NRIX Stock: Price, Earnings History and SEC Filings
Nurix Therapeutics, Inc. (NRIX) last traded at $26.80, down 1.18% on the latest session and up 13.0% over the past month. In its most recent reported quarter (Aug 2026) earnings per share were $4.73 against an analyst estimate of $-0.56, a beat of 944.6%.
$26.80 -1.18%
1 month+13.03%
52-week high$28.23
52-week low$11.67
Volume2.31M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NRIX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Aug 2026 | Oct 12, 2026 | $4.73 | $-0.56 | +944.64% |
| May 2026 | Jul 9, 2026 | $-0.81 | $-0.73 | -10.96% |
| Feb 2026 | Apr 8, 2026 | $-0.79 | $-0.76 | -3.95% |
| Nov 2025 | Jan 28, 2026 | $-0.82 | $-0.84 | +2.38% |
NRIX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NRIX
SEC filing data is not available right now. You can search for NRIX on SEC EDGAR.
NRIX news
- Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?Oct 28, 2026 · finance.yahoo.com
- Could You Have Seen The Run In Kymera Stock Coming?Oct 26, 2026 · trefis.com
- Roche's 9M 2026 Sales Rise on Strong Drug Demand, Pipeline AdvancesOct 22, 2026 · finance.yahoo.com
- What Nurix Therapeutics Stock's Profit Turnaround Means For ShareholdersOct 22, 2026 · finance.yahoo.com
- Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?Oct 19, 2026 · finance.yahoo.com
About Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX) is a US-listed public company on Nasdaq.